Last updated on April 24, 2014 at 11:28 EDT

Circassia’s Hay Fever Treatment Improves Patients’ Allergy Symptoms in Phase II Clinical Trial

September 27, 2011

OXFORD, England, September 27, 2011 /PRNewswire/ –

Circassia Ltd, a specialty biopharmaceutical company focused on allergy,
today announced positive phase II clinical results showing that its
ToleroMune(R) hay fever vaccine substantially improved patients’ allergy
symptoms compared with those on placebo. The treatment was extremely well

During the randomised, double-blind, placebo-controlled phase II study
conducted in 50 hay fever sufferers in Quebec, Canada, patients received
four doses from one of five different treatment regimes over a 12-week
period. Five weeks later, investigators tested the patients’ skin and eye
responses to grass pollen. The results show that the treatment reduced
allergic symptoms in patients’ eyes by up to 30% more than placebo. In
addition, the therapy improved early and late skin reactions by up to 54%
and 19% above placebo respectively. The ToleroMune T-cell vaccine had a
similar safety profile to placebo.

Following these results, Circassia has initiated the final phase II
trial of its hay fever treatment. The double-blind, placebo-controlled study
is underway in Kingston, Canada in 280 volunteers, and will assess the
effectiveness of the ToleroMune T-cell vaccine at improving patients’ nasal
symptoms and eye responses when exposed to grass pollen in an exposure

“Achieving these clinical results is particularly encouraging as hay
fever is an extremely common allergy, which can have a major impact on
sufferers,” said Steve Harris, Circassia’s CEO. “Many current therapies
provide short-term symptom relief only, while traditional immunotherapies
can require specialist treatment over several years to address the
underlying disease. Circassia’s latest results follow earlier successful
studies in a range of different allergies. Our clinical data show that
Circassia’s T-cell vaccines have the potential to revolutionise allergy
therapy, and these recent results give us the confidence to proceed with the
final phase II testing of our unique hay fever treatment.”

About Circassia’s allergy T-cell vaccines

Circassia is developing a range of allergy T-cell vaccines based on its
proprietary ToleroMune(R) technology. The company has successfully completed
a number of phase II studies with its cat, house dust mite, ragweed and
grass allergy therapies. Clinical results show that short treatment regimes
with Circassia’s T-cell vaccines can greatly reduce patients’ allergic
responses, without the need for adjuvants or other immune stimulators, while
proving extremely well tolerated. As a result, the treatments offer major
potential clinical benefits compared with existing therapies, and have
significant market opportunities. Over 150 million people suffer from
allergic rhinitis in the US and Europe, and approximately 15% – 25% of
people in these countries are sensitive to grass pollen. As a result, the
current allergy treatment market is valued at approximately $12 billion per

About Circassia

Circassia was founded in 2006 by a team of highly experienced
biotechnology scientists and entrepreneurs, and is chaired by the former
Chairman of GlaxoSmithKline, Sir Richard Sykes. The company is based in the
UK on the Oxford Science Park, and in Hamilton, Canada, where its joint
venture Adiga Life Sciences is located. Its ToleroMune technology was
developed originally by scientists at Imperial College, London. Having
successfully completed four fundraising rounds, Circassia has raised
approximately GBP93 million ($159 million) and is backed by a syndicate of
world-class venture capital and institutional investors, including Imperial
Innovations and Invesco Perpetual.

        Steve Harris
        Tel: +44 (0)1865 784574


        Rob Budge
        RJB Communications
        Tel: +44 (0)1865 760969
        Mobile: +44 (0)7710 741241

SOURCE Circassia

Source: PR Newswire